secwatch.observer — SEC 8-K summary
======================================

Issuer:     Denali Therapeutics Inc. (DNLI)
CIK:        0001714899
Form:       8-K
Filed at:   2023-02-27T23:59:59+00:00
Accession:  0001714899-23-000048
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Denali Therapeutics Q4 2022 net loss $98.7M; cash $1.34B; guides 2023 opex up 25-30%
--------------------------------------------------------------------------------

- Net loss $98.7M in Q4 2022 vs $75.3M in Q4 2021; full year net loss $326.0M vs $290.6M.
- Collaboration revenue $10.3M Q4, $108.5M FY2022; R&D expenses $92.1M Q4, $358.7M FY2022.
- Cash and marketable securities $1.34B as of Dec 31, 2022; raised $296.2M net in Oct 2022 public offering.
- 2023 guidance: cash operating expenses expected to increase 25-30% YoY, partially offset by up to $50M in partnership payments.
- Phase 2/3 COMPASS study for DNL310 (MPS II) enrolling; Phase 3 LIGHTHOUSE for BIIB122 (Parkinson's) initiated; Phase 2 HIMALAYA for DNL788 (ALS) recruitment completion expected end 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1714899/000171489923000048/0001714899-23-000048-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1714899/000171489923000048/dnli-20230227.htm
  HTML page:      https://secwatch.observer/filing/0001714899-23-000048

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer